FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SANTA CLARA, Calif., Sept. 12, 2016 -- Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today that the company’s CEO, Mike Kleine, was interviewed on Bloomberg Radio’s “Taking Stock” on September, 12th, 2016 at 3:15pm EDT.
In the interview, Mr. Kleine discussed the commercial momentum of the miraDry procedure and the significant market opportunity for the Company. The interview can be viewed at
http://www.bloomberg.com/news/audio/2016-09-12/miramar-labs-wipes-away-sweat-glands-and-odor-audio
“This interview with Bloomberg further demonstrates there is a growing interest in our company and the miraDry procedure. This is only one of the several steps we are taking to raise awareness and tell our story to current and potential investors, customers and patients,” commented Mr. Kleine.
About Miramar Labs
Miramar Labs, Inc., is a global medical device company dedicated to bringing innovative and clinically proven applications to treat unmet needs in the aesthetic marketplace. Supported by rigorous clinical research, Miramar Labs is focused on addressing medical conditions for which there are significant unmet clinical needs. The company’s first priority is the treatment of bothersome underarm sweat, an issue that hundreds of millions of people deal with daily. The miraDry® procedure has an established safety and efficacy profile with over 70,000 patients treated worldwide. Physicians and patients are encouraged to visit www.miramarlabs.com or www.miradry.com for additional information.
Contacts: Investors: Brigid Makes Sr. Vice President & CFO 408-579-8700 [email protected] Nick Laudico or Zack Kubow The Ruth Group 646-536-7030 / 7020 [email protected] [email protected] Media/Other: Robert Ellis Vice President of Global Marketing Miramar Labs Phone: 408-579-8706 Email: [email protected] Chris Hippolyte The Ruth Group 646-536-7023 [email protected]
